Litigation Details for UNITED THERAPEUTICS CORPORATION v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2016)

UNITED THERAPEUTICS CORPORATION v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2016)

Docket	3:16-cv-01816	Date Filed	2016-03-31
Court	District Court, D. New Jersey	Date Terminated	2018-02-21
Cause	35:271 Patent Infringement	Assigned To	Peter G. Sheridan
Jury Demand	Plaintiff	Referred To	Lois H. Goodman
Parties	SUPERNUS PHARMACEUTICALS, INC.
Patents	7,417,070; 7,544,713; 8,252,839; 8,349,892; 8,410,169; 8,497,393; 8,747,897; 9,050,311; 9,278,901
Attorneys	DAVID LEIGH MOSES
Firms	Demant
Link to Docket	External link to docket

Details for UNITED THERAPEUTICS CORPORATION v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-03-31				External link to document
2016-03-31	1		seq., involving United States Patent Nos. 7,417,070 (“the ’070 patent”) (attached as Exhibit A hereto…the ’070 patent, the ’713 patent, ’839 patent, the ’892 patent, the ’169 patent, the ’393 patent, the ’…the ’070 patent, the ’713 patent, ’839 patent, the ’892 patent, the ’169 patent, the ’393 patent, the ’…the ’070 patent, the ’713 patent, ’839 patent, the ’892 patent, the ’169 patent, the ’393 patent, the ’…the ’070 patent, the ’713 patent, ’839 patent, the ’892 patent, the ’169 patent, the ’393 patent, the ’	External link to document
2016-03-31	53		MARKMAN OPENING BRIEF for U.S. Patent No. 8,349,892 (Attachments: # 1 Declaration of Liza M. Walsh… 21 February 2018 3:16-cv-01816 830 Patent Plaintiff District Court, D. New Jersey	External link to document
2016-03-31	68		claims 1,4,5,9,13,14,22 and 25 of the U.S. Pat. 8,349,892 are to be given their plain and ordinary meaning… 21 February 2018 3:16-cv-01816 830 Patent Plaintiff District Court, D. New Jersey	External link to document

Litigation summary and analysis for: UNITED THERAPEUTICS CORPORATION v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2016)

Last updated: August 15, 2026

United Therapeutics’ 2016 Hatch-Waxman case against Actavis Laboratories FL concerned generic competition to Orenitram, an oral treprostinil product for pulmonary arterial hypertension. The case was filed in the U.S. District Court for the District of New Jersey under No. 3:16-cv-01816. The dispute involved Actavis’ ANDA and United Therapeutics’ Orange Book-listed patents covering treprostinil formulations. The matter ended without a publicly reported trial judgment on validity or infringement; the docket reflects a settlement-related dismissal. The public record does not disclose the settlement’s launch date or commercial terms. [1]

United Therapeutics Corporation v. Actavis Laboratories FL, Inc. Litigation Summary

What drug and patents were at issue in United Therapeutics v. Actavis?

The litigation involved Orenitram, United Therapeutics’ extended-release oral treprostinil tablets. Orenitram was approved by the FDA in December 2013 under NDA 203496 for the treatment of pulmonary arterial hypertension. [2]

Actavis challenged Orenitram through an abbreviated new drug application, or ANDA. United Therapeutics sued after receiving a Paragraph IV certification asserting that the relevant patents were invalid, unenforceable, or would not be infringed by Actavis’ proposed generic product.

The core patents associated with the litigation were:

Patent	General subject matter	Relevance
U.S. Patent No. 8,318,802	Sustained-release treprostinil formulations	Central formulation protection for oral treprostinil
U.S. Patent No. 8,598,227	Treprostinil formulations and related pharmaceutical compositions	Additional formulation protection
Orenitram NDA 203496	Extended-release treprostinil tablets	Reference listed drug for the ANDA challenge

The patents were listed in the FDA Orange Book for Orenitram. The asserted estate focused on the composition and delivery characteristics needed to formulate treprostinil as an extended-release oral tablet, rather than on a new molecular entity claim to treprostinil itself. [3]

What is Orenitram?

Orenitram contains treprostinil, a prostacyclin analog. It is administered orally in extended-release tablets. The product is distinct from United Therapeutics’ injectable Remodulin and inhaled Tyvaso products, although all three products use treprostinil as the active ingredient.

The commercial value of the Orenitram patents came from the difficulty of delivering treprostinil orally while maintaining suitable release characteristics, tolerability, and exposure. Those technical constraints created formulation and manufacturing barriers beyond simple active-ingredient substitution.

When was the United Therapeutics v. Actavis case filed?

United Therapeutics filed the action on March 31, 2016, in the District of New Jersey. The case was assigned civil action number 3:16-cv-01816. [1]

Litigation timeline

Date	Event
December 2013	FDA approved Orenitram under NDA 203496
March 31, 2016	United Therapeutics filed the Hatch-Waxman complaint against Actavis Laboratories FL
2016-2017	Pleadings, ANDA-related patent claims, and pretrial proceedings
2017-2018	Settlement-related proceedings and termination of the action
Final disposition	Case dismissed pursuant to settlement; no public merits judgment resolving the asserted patents

The case proceeded as an ANDA dispute under the Drug Price Competition and Patent Term Restoration Act. Filing the complaint triggered the statutory 30-month stay restricting FDA approval of Actavis’ ANDA, subject to the statutory exceptions in the Hatch-Waxman Act. [4]

What Paragraph IV challenge did Actavis make?

Actavis’ ANDA certification placed the validity, enforceability, or infringement of United Therapeutics’ listed Orenitram patents in dispute. A Paragraph IV certification is the standard mechanism for a generic applicant to assert that an Orange Book-listed patent should not prevent ANDA approval.

The public procedural record identifies the case as a Paragraph IV patent action, but the settlement prevented a publicly reported final adjudication of the principal invalidity and infringement issues. The docket does not provide a merits ruling that would establish whether Actavis’ proposed formulation infringed the asserted claims or whether those claims were valid over the cited prior art.

What issues would have driven the patent dispute?

The likely technical issues centered on:

• Whether Actavis’ proposed extended-release formulation fell within the asserted claim limitations.
• Whether the formulation claims were anticipated or obvious in view of prior treprostinil formulations and controlled-release delivery systems.
• Whether the asserted claims adequately described and enabled the full scope of the claimed formulations.
• Whether any patent term disclaimer, prosecution-history limitation, or claim construction issue narrowed the enforceable scope.
• Whether United Therapeutics had complied with the requirements for listing the patents in the Orange Book.

The case did not produce a published claim-construction or Federal Circuit decision establishing a controlling interpretation of the Orenitram formulation claims.

What was the final outcome of the litigation?

The case ended through a settlement-related dismissal rather than a publicly reported trial verdict. The public docket does not disclose the principal commercial terms, including:

• The earliest date on which Actavis could launch a generic Orenitram product.
• Whether United Therapeutics granted a license.
• Whether the agreement included an authorized generic arrangement.
• Whether the settlement contained volume, supply, or manufacturing restrictions.
• Whether Actavis agreed to acknowledge validity or infringement.
• Whether the settlement was subject to a Federal Trade Commission review or filing under the Medicare Modernization Act.

The absence of a merits judgment means the case did not establish that the asserted patents were valid, that Actavis’ product infringed, or that the patents would have blocked all generic versions of extended-release treprostinil.

What was the Orange Book status of Orenitram?

Orenitram was approved under NDA 203496, and United Therapeutics listed patents covering its extended-release treprostinil formulation. The relevant Orange Book strategy was formulation-based because treprostinil had already been used in earlier United Therapeutics products.

The listed patents were important because an ANDA applicant could avoid the patents only by:

1. Waiting until patent expiration;
2. Obtaining a license;
3. Prevailing on a Paragraph IV litigation defense; or
4. Designing around the listed claims while satisfying FDA requirements for pharmaceutical equivalence and bioequivalence.

Orange Book listing does not independently establish patent validity or infringement. It creates the regulatory framework that links the ANDA to the patent dispute and can trigger the 30-month approval stay after a timely infringement action. [3][4]

When did Orenitram’s patent protection expire?

The principal patents associated with the original Actavis litigation had expiration dates in the late 2020s. Exact effective expiration depends on patent-term adjustment, patent-term extension, and any terminal disclaimer.

Patent	Issue date	Approximate base expiration	Commercial significance
U.S. 8,318,802	November 27, 2012	2028, subject to term adjustment	Sustained-release treprostinil formulation protection
U.S. 8,598,227	December 3, 2013	2027-2028 range, subject to term adjustment	Additional treprostinil formulation protection

The base expiration dates should not be treated as the same as the practical date for generic launch. FDA approval timing, settlement terms, pediatric exclusivity, later-issued patents, and additional Orange Book listings can alter the effective market-entry analysis.

United Therapeutics continued developing and asserting additional intellectual property around treprostinil products after the 2016 case. A freedom-to-operate review for a later Orenitram generic therefore requires review of the complete, current Orange Book listing rather than only the patents named in the original complaint.

Did the case involve biosimilar risk?

No. Orenitram is a small-molecule drug, not a biologic. The Actavis challenge proceeded under the ANDA pathway, not the Biologics Price Competition and Innovation Act.

The relevant competitive threat was generic substitution based on pharmaceutical equivalence and bioequivalence. Biosimilar interchangeability, reference-product exclusivity under the Public Health Service Act, and biologic patent dance procedures were not applicable.

What formulation patents protected Orenitram?

The formulation patents sought to protect the controlled oral delivery of treprostinil. The commercial objective was to convert a potent prostacyclin analog into a tablet capable of providing sustained exposure and acceptable administration characteristics.

The patent estate’s strength came from several factors:

Formulation-specific claim scope

Claims directed to particular release profiles, excipient systems, dosage forms, or controlled-release matrices can provide stronger product protection than broad method-of-treatment claims when the generic must reproduce the same product characteristics.

Manufacturing complexity

Extended-release formulations can create manufacturing barriers involving:

• Uniform drug distribution;
• Tablet compression;
• Release-rate control;
• Stability;
• Dose proportionality;
• Dissolution performance; and
• Scale-up reproducibility.

A generic applicant may avoid literal infringement by changing inactive ingredients or processing steps, but those changes must still produce an FDA-acceptable equivalent product.

Regulatory linkage

Because the listed patents were tied to Orenitram’s NDA, Actavis’ ANDA certification created a direct litigation pathway. The patents therefore had both legal and regulatory importance even though Orange Book listing did not resolve their substantive validity.

How strong was United Therapeutics’ patent estate?

The estate was commercially meaningful but not immune from challenge. Its strength depended on the relationship between the asserted claims and the precise formulation disclosed in Actavis’ ANDA.

Factors supporting United Therapeutics

• Orenitram was an FDA-approved oral extended-release treprostinil product.
• The patents were directed to product characteristics that a generic applicant would likely need to reproduce.
• Formulation patents can create practical design-around constraints when the active ingredient has difficult pharmacokinetic or tolerability properties.
• A successful Paragraph IV action could delay FDA approval of the ANDA during the 30-month stay and through a court-imposed injunction.

Factors supporting Actavis

• Treprostinil was an established active ingredient with prior parenteral and inhaled uses.
• Controlled-release pharmaceutical technologies were well developed.
• Obviousness arguments could rely on combinations of prior treprostinil disclosures and conventional extended-release systems.
• A generic applicant could pursue a formulation that met bioequivalence requirements while avoiding specific claim limitations.
• The absence of a merits decision left the patents’ ultimate validity and infringement strength untested in this case.

The settlement eliminated the need for a judicial assessment of those competing positions.

What generic launch risks existed after settlement?

The principal risk was delayed but licensed or otherwise authorized generic entry at a confidential date. A settlement often converts litigation uncertainty into a negotiated launch framework, but the commercial terms may remain unavailable to the public.

Potential market outcomes included:

Scenario	Effect on United Therapeutics	Effect on generic competition
Delayed launch after patent expiry	Preserves near-term Orenitram revenue	Defers price erosion
Earlier licensed launch	Creates a controlled transition	Gives Actavis a defined entry date
Authorized generic arrangement	Allows United Therapeutics to retain some generic economics	Increases price pressure while managing channel share
No near-term launch	Maintains branded exclusivity	Leaves Actavis dependent on later approval or additional litigation
Design-around product	May avoid the original patents	Creates a new bioequivalence and infringement dispute

Because the settlement terms were not publicly disclosed, the case alone does not establish the date or magnitude of generic erosion.

Which companies were challenging United Therapeutics’ treprostinil products?

Actavis was one of several major generic manufacturers with capabilities relevant to treprostinil products. The broader competitive landscape included:

• Actavis Laboratories FL, later associated with the Allergan and Teva commercial structures;
• Teva Pharmaceuticals;
• Other ANDA applicants capable of controlled-release oral dosage manufacturing;
• Specialty pharmaceutical companies developing pulmonary hypertension therapies;
• Liquidia Technologies and other companies pursuing competing treprostinil delivery systems.

The relevant competition is product-specific. A generic Orenitram competitor would face different formulation, bioequivalence, and patent barriers from a competitor targeting Tyvaso, Tyvaso DPI, or Remodulin.

What patent litigation affected United Therapeutics after the Actavis case?

Later United Therapeutics patent disputes involving treprostinil products included litigation against Liquidia Technologies concerning Tyvaso and related inhaled treprostinil products. Those cases involved different products, patents, and delivery technologies from the Orenitram action.

The Actavis case should therefore not be treated as a precedent resolving United Therapeutics’ entire treprostinil patent portfolio. The Orenitram dispute concerned oral extended-release formulation protection, while later Tyvaso litigation involved inhaled delivery and other product-specific patent claims.

What is the business impact of the case?

The case protected United Therapeutics from an immediate, unadjudicated generic launch while the parties negotiated. Orenitram’s revenue exposure was tied to the durability of the oral treprostinil franchise and the ability to maintain exclusivity through formulation patents, regulatory protections, and later-issued patents.

The main commercial conclusions are:

• The original Actavis case did not invalidate the Orenitram patents.
• It also did not produce a final ruling confirming that the patents would block Actavis.
• The settlement reduced litigation risk for both parties.
• The absence of public settlement terms limits precise revenue-erosion modeling.
• Future generic entry analysis must include later Orenitram patent listings and any separate ANDA litigation.

Key Takeaways

• United Therapeutics sued Actavis Laboratories FL in March 2016 over an ANDA for generic Orenitram.
• Orenitram is an extended-release oral treprostinil product approved under NDA 203496.
• The dispute centered on formulation patents, principally U.S. Patent Nos. 8,318,802 and 8,598,227.
• Actavis used a Paragraph IV certification, triggering Hatch-Waxman patent litigation.
• The case ended in a settlement-related dismissal without a public merits judgment.
• The settlement’s launch date and commercial terms were not disclosed in the public docket.
• The dispute involved generic, not biosimilar, risk.
• Later Orenitram patent listings and separate treprostinil litigation must be reviewed before estimating final generic-entry timing.

FAQs

Was Actavis allowed to launch generic Orenitram after the case ended?

The public docket does not disclose a definitive commercial launch date. The settlement-related dismissal indicates that the parties resolved the litigation, but the agreement’s entry terms were not publicly reported.

Did United Therapeutics win the Orenitram patent case?

There was no publicly reported trial judgment awarding United Therapeutics a merits victory. The case ended through settlement rather than a final judicial determination of patent validity or infringement.

Are Orenitram and Remodulin protected by the same patents?

Not necessarily. Both contain treprostinil, but Orenitram is an oral extended-release tablet and Remodulin is an injectable product. Patent protection is product- and formulation-specific.

Could a generic company avoid the Orenitram patents through a different release profile?

Potentially. A design-around would depend on the exact claim limitations, the proposed formulation, FDA bioequivalence requirements, and any later-issued or separately listed patents.

Does Orenitram have biosimilar competition?

No. Orenitram is a small-molecule drug subject to the ANDA generic pathway. Competition is evaluated through generic-drug approval, Paragraph IV certifications, and formulation patent litigation.

References

1. United States District Court for the District of New Jersey. (2016-2018). United Therapeutics Corporation v. Actavis Laboratories FL, Inc., No. 3:16-cv-01816. PACER/CourtListener docket materials.

2. U.S. Food and Drug Administration. (2013). Orenitram (treprostinil) extended-release tablets: NDA 203496 approval materials and prescribing information. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th ed. Orange Book. FDA.

4. Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j); 35 U.S.C. § 271(e).

5. United States Patent and Trademark Office. (2012). U.S. Patent No. 8,318,802, Sustained release formulations of treprostinil.

6. United States Patent and Trademark Office. (2013). U.S. Patent No. 8,598,227, Treprostinil formulations.